5-diphenylacetamido-indirubin-3-oxime as a novel mitochondria-targeting agent with anti-leukemic activities
- Authors
- Song, Ju Han; Lee, Jung-Eun; Cho, Kyung-Min; Park, Su-Ho; Kim, Hyeoung-Joon; Kim, Yong-Chul; Kim, Tae Sung
- Issue Date
- 5월-2016
- Publisher
- WILEY
- Keywords
- indirubin derivative; leukemia; mitochondria; drug-resistance; chemotherapy
- Citation
- MOLECULAR CARCINOGENESIS, v.55, no.5, pp.611 - 621
- Indexed
- SCIE
SCOPUS
- Journal Title
- MOLECULAR CARCINOGENESIS
- Volume
- 55
- Number
- 5
- Start Page
- 611
- End Page
- 621
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/88721
- DOI
- 10.1002/mc.22307
- ISSN
- 0899-1987
- Abstract
- Current treatment for leukemia largely depends on chemotherapy. Despite the progress in treatment efficacy of chemotherapy, a poor outcome consequent upon chemoresistance against conventional anti-cancer drugs still remains to be solved. In this study, we report 5-diphenylacetamido-indirubin-3-oxime (LDD398) as a novel mitochondria-targeting anti-leukemic agent, which is a derivative of indirubin used in traditional medicine. Treatment with LDD398 resulted in caspase activation, cell death, and growth arrest at G2/M phases in leukemia cells. Interestingly, LDD398 quickly collapsed mitochondrial membrane potential (MMP) within 1h, accompanied by cytochrome c release into cytosol and severe depletion of cellular ATP. However, the LDD398-induced cellular events was significantly mitigated by blockage of mitochondrial permeability transition pore (MPTP) opening with chemical and genetic modifications, strongly supporting that LDD398 executes its anti-leukemic activity via an inappropriate opening of MPTP and a consequent depletion of ATP. The most meaningful finding was the prominent effectiveness of LDD398 on primary leukemia cells and also on malignant leukemia cells resistant to anticancer drugs. Our results demonstrate that, among a series of indirubin derivatives, LDD398 induces leukemia cell death via a different mode from indirubin or conventional chemotherapeutics, and can be employed as a potent anti-cancer agent in the treatment for newly diagnosed and relapsed leukemia. (c) 2015 Wiley Periodicals, Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Life Sciences and Biotechnology > Division of Life Sciences > 1. Journal Articles
- Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.